Gufic Biosciences receives DCGI approval for Thymosin Alpha-1 to treat Covid-19
Immunocin, an Immuno-modulator drug, significantly reduced the risk of death in the Phase 3 clinical trial in adult patients with moderate-to-severe Covid-19
Immunocin, an Immuno-modulator drug, significantly reduced the risk of death in the Phase 3 clinical trial in adult patients with moderate-to-severe Covid-19
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
Under the terms of the agreement, Vipergen will apply its in-living-cell DNA-encoded library (DEL) screening platform to discover novel small-molecule compounds that bind to a selected Theseus kinase target
Lupin is committed to providing new affordable treatment options to healthcare providers and patients
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
It is currently available in tablet and injectable dosage forms
The two-day event will showcase achievements and address issues pertaining to the industry
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
The symposium was organized by the Gut Microbiota and Probiotic Science Foundation (India) and Medanta Institute of Education and Research, Gurugram, and Amity University, Gurugram
Supply increase to help meet growing global demand
Subscribe To Our Newsletter & Stay Updated